- Home
- LYEL vs CION Comparison
LYEL vs CION Comparison
Compare LYEL & CION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LYEL | CION |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.1M | 464.0M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | LYEL | CION |
|---|---|---|
| Price | $22.11 | $8.15 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 3 | 1 |
| Target Price | ★ $25.00 | $8.50 |
| AVG Volume (30 Days) | 95.9K | ★ 504.3K |
| Earning Date | 01-01-0001 | 03-23-2026 |
| Dividend Yield | N/A | ★ 14.80% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $61,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.55 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $7.73 |
| 52 Week High | $45.00 | $12.57 |
Technical Indicators
Market Signals| Indicator | LYEL | CION |
|---|---|---|
| Relative Strength Index (RSI) | 40.79 | 30.58 |
| Support Level | $21.27 | N/A |
| Resistance Level | $27.30 | $9.50 |
| Average True Range (ATR) | 2.12 | 0.24 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 21.95 | 38.05 |
Price Performance
Historical ComparisonAbout LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About CION CION Investment Corporation
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.